Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 6/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7865633 | 0.93 | PIK3CA (0.43) | PIK3CACREBBPGPR142ABL1PIK3CG | |
| SCHEMBL3715967 | 0.87 | CREBBP (0.47) | PIK3CACREBBPGPR142ABL1 | |
| SCHEMBL15522763 | 0.85 | PIK3CA (0.44) | PIK3CACREBBPGPR142 | |
| SCHEMBL3717345 | 0.85 | PIK3CA (0.45) | PIK3CACREBBPGPR142ABL1PIK3CG | |
| SCHEMBL3716268 | 0.84 | PIK3CA (0.42) | PIK3CACREBBPGPR142ABL1 | |
| SCHEMBL3753317 | 0.83 | PIK3CA (0.44) | PIK3CAGPR142ABL1 | |
| SCHEMBL3757616 | 0.82 | CREBBP (0.47) | PIK3CACREBBPGPR142ABL1 | |
| SCHEMBL15603621 | 0.82 | LMNA (0.45) | PIK3CACREBBPGPR142ABL1 | |
| SCHEMBL3757188 | 0.82 | BTK (0.42) | PIK3CACREBBP | |
| SCHEMBL3716243 | 0.81 | MTNR1B (0.44) | PIK3CAGPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | claimed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885CREBBP 259/4885GPR142 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.